Dupont Capital Management Corp Has $3.77 Million Stake in Eli Lilly and Company (LLY)

Dupont Capital Management Corp lifted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 230.0% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 45,831 shares of the company’s stock after acquiring an additional 31,941 shares during the quarter. Dupont Capital Management Corp’s holdings in Eli Lilly and were worth $3,772,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently modified their holdings of the company. Joel Isaacson & Co. LLC raised its position in shares of Eli Lilly and by 1.5% during the first quarter. Joel Isaacson & Co. LLC now owns 3,364 shares of the company’s stock worth $283,000 after acquiring an additional 50 shares during the last quarter. Sumitomo Life Insurance Co. raised its position in shares of Eli Lilly and by 4.4% during the second quarter. Sumitomo Life Insurance Co. now owns 32,507 shares of the company’s stock worth $2,675,000 after acquiring an additional 1,370 shares during the last quarter. Russell Investments Group Ltd. raised its position in shares of Eli Lilly and by 7.8% during the second quarter. Russell Investments Group Ltd. now owns 671,327 shares of the company’s stock worth $55,258,000 after acquiring an additional 48,706 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of Eli Lilly and by 93.6% during the first quarter. Renaissance Technologies LLC now owns 2,980,400 shares of the company’s stock worth $250,681,000 after acquiring an additional 1,441,200 shares during the last quarter. Finally, Stephens Inc. AR raised its position in shares of Eli Lilly and by 4.5% during the first quarter. Stephens Inc. AR now owns 44,023 shares of the company’s stock worth $3,703,000 after acquiring an additional 1,901 shares during the last quarter. Institutional investors own 75.72% of the company’s stock.

LLY has been the subject of a number of analyst reports. Piper Jaffray Companies restated a “buy” rating and set a $103.00 price objective on shares of Eli Lilly and in a research report on Thursday, August 31st. Zacks Investment Research upgraded Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price objective for the company in a research report on Monday, July 17th. Jefferies Group LLC restated a “buy” rating and set a $89.00 price objective (down from $94.00) on shares of Eli Lilly and in a research report on Thursday, August 24th. Cowen and Company restated a “buy” rating and set a $95.00 price objective on shares of Eli Lilly and in a research report on Wednesday, October 4th. Finally, Berenberg Bank restated a “buy” rating and set a $100.00 price objective on shares of Eli Lilly and in a research report on Thursday, July 27th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $88.42.

ILLEGAL ACTIVITY WARNING: “Dupont Capital Management Corp Has $3.77 Million Stake in Eli Lilly and Company (LLY)” was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this article on another publication, it was illegally copied and republished in violation of United States & international trademark and copyright law. The legal version of this article can be read at https://ledgergazette.com/2017/10/10/dupont-capital-management-corp-has-3-77-million-stake-in-eli-lilly-and-company-lly.html.

Shares of Eli Lilly and Company (NYSE:LLY) opened at 87.05 on Tuesday. The stock’s 50 day moving average price is $82.49 and its 200 day moving average price is $82.14. The company has a market cap of $91.84 billion, a P/E ratio of 37.67 and a beta of 0.34. Eli Lilly and Company has a 12-month low of $64.18 and a 12-month high of $89.09.

Eli Lilly and (NYSE:LLY) last announced its earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.06. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The firm had revenue of $5.82 billion during the quarter, compared to analyst estimates of $5.60 billion. During the same quarter in the prior year, the company earned $0.86 EPS. The business’s revenue was up 7.8% compared to the same quarter last year. On average, analysts forecast that Eli Lilly and Company will post $4.16 EPS for the current year.

In other news, major shareholder Lilly Endowment Inc sold 180,000 shares of the stock in a transaction that occurred on Thursday, August 31st. The stock w

Other institutional investors and hedge funds also recently modified their holdings of the company. Joel Isaacson & Co. LLC raised its position in shares of Eli Lilly and by 1.5% during the first quarter. Joel Isaacson & Co. LLC now owns 3,364 shares of the company’s stock worth $283,000 after acquiring an additional 50 shares during the last quarter. Sumitomo Life Insurance Co. raised its position in shares of Eli Lilly and by 4.4% during the second quarter. Sumitomo Life Insurance Co. now owns 32,507 shares of the company’s stock worth $2,675,000 after acquiring an additional 1,370 shares during the last quarter. Russell Investments Group Ltd. raised its position in shares of Eli Lilly and by 7.8% during the second quarter. Russell Investments Group Ltd. now owns 671,327 shares of the company’s stock worth $55,258,000 after acquiring an additional 48,706 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of Eli Lilly and by 93.6% during the first quarter. Renaissance Technologies LLC now owns 2,980,400 shares of the company’s stock worth $250,681,000 after acquiring an additional 1,441,200 shares during the last quarter. Finally, Stephens Inc. AR raised its position in shares of Eli Lilly and by 4.5% during the first quarter. Stephens Inc. AR now owns 44,023 shares of the company’s stock worth $3,703,000 after acquiring an additional 1,901 shares during the last quarter. Institutional investors own 75.72% of the company’s stock.

LLY has been the subject of a number of analyst reports. Piper Jaffray Companies restated a “buy” rating and set a $103.00 price objective on shares of Eli Lilly and in a research report on Thursday, August 31st. Zacks Investment Research upgraded Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price objective for the company in a research report on Monday, July 17th. Jefferies Group LLC restated a “buy” rating and set a $89.00 price objective (down from $94.00) on shares of Eli Lilly and in a research report on Thursday, August 24th. Cowen and Company restated a “buy” rating and set a $95.00 price objective on shares of Eli Lilly and in a research report on Wednesday, October 4th. Finally, Berenberg Bank restated a “buy” rating and set a $100.00 price objective on shares of Eli Lilly and in a research report on Thursday, July 27th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $88.42.

ILLEGAL ACTIVITY WARNING: “Dupont Capital Management Corp Has $3.77 Million Stake in Eli Lilly and Company (LLY)” was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this article on another publication, it was illegally copied and republished in violation of United States & international trademark and copyright law. The legal version of this article can be read at https://ledgergazette.com/2017/10/10/dupont-capital-management-corp-has-3-77-million-stake-in-eli-lilly-and-company-lly.html.

Shares of Eli Lilly and Company (NYSE:LLY) opened at 87.05 on Tuesday. The stock’s 50 day moving average price is $82.49 and its 200 day moving average price is $82.14. The company has a market cap of $91.84 billion, a P/E ratio of 37.67 and a beta of 0.34. Eli Lilly and Company has a 12-month low of $64.18 and a 12-month high of $89.09.

Eli Lilly and (NYSE:LLY) last announced its earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.06. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The firm had revenue of $5.82 billion during the quarter, compared to analyst estimates of $5.60 billion. During the same quarter in the prior year, the company earned $0.86 EPS. The business’s revenue was up 7.8% compared to the same quarter last year. On average, analysts forecast that Eli Lilly and Company will post $4.16 EPS for the current year.

In other news, major shareholder Lilly Endowment Inc sold 180,000 shares of the stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $81.06, for a total value of $14,590,800.00. Following the completion of the transaction, the insider now owns 123,865,804 shares of the company’s stock, valued at approximately $10,040,562,072.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold a total of 990,000 shares of company stock valued at $82,949,650 in the last three months. Corporate insiders own 0.20% of the company’s stock.

Eli Lilly and Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply